Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?

Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has also outperformed the sector as well as the S&P 500, as seen in the chart below.PFE...

PFE : 29.66 (-0.30%)
NVO : 134.88 (+2.14%)
LLY : 915.04 (+1.11%)
ABRYSVOâ„¢: Pfizer Canada's Newly Publicly Funded Vaccine a Step Towards National RSV Prevention in Older Adults

/CNW/ - Today, Pfizer Canada ULC announced that ABRYSVOâ„¢ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus...

PFE : 29.66 (-0.30%)
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung cancer...

AZN : 78.90 (+0.41%)
PFE : 29.66 (-0.30%)
MRK : 117.23 (-1.19%)
LLY : 915.04 (+1.11%)
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population.The regulatory body approved Kisqali in combination with an aromatase inhibitor (AI) for...

NVS : 115.98 (+0.01%)
PFE : 29.66 (-0.30%)
LLY : 915.04 (+1.11%)
3 Magnificent Dividend Stocks With Yields Above 5% to Buy Now and Hold Forever

After underperforming over the past few years, these stocks offer huge dividend yields that could keep rising throughout your retirement.

WPC : 63.12 (-0.65%)
VZ : 43.94 (+0.14%)
PFE : 29.66 (-0.30%)
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030

These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.

MRK : 117.23 (-1.19%)
PFE : 29.66 (-0.30%)
MRNA : 68.02 (-2.63%)
VRTX : 477.90 (+0.79%)
VKTX : 68.16 (+5.76%)
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%

Novartis NVS announced positive data on breast cancer drug Kisqali (ribociclib) from the late-stage study, NATALEE.This late-breaking data from this four-year post-hoc analysis was presented at the European...

NVS : 115.98 (+0.01%)
PFE : 29.66 (-0.30%)
LLY : 915.04 (+1.11%)
BAYRY : 8.0800 (+3.72%)
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)

Telemedicine once seemed like it was going to revolutionize healthcare.

LLY : 915.04 (+1.11%)
PFE : 29.66 (-0.30%)
NVO : 134.88 (+2.14%)
TDOC : 9.18 (+0.99%)
AMZN : 189.87 (+1.85%)
NVDA : 117.87 (+3.97%)
SFIX : 4.18 (+0.97%)
VKTX : 68.16 (+5.76%)
ALT : 7.57 (+1.88%)
RHHBY : 39.4600 (-0.38%)
HIMS : 16.92 (+3.74%)
Lilly Gets FDA Approval for Eczema Drug Ebglyss

Eli Lilly and Company LLY announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, also called eczema. Ebglyss is approved...

NVS : 115.98 (+0.01%)
BIIB : 201.44 (+1.95%)
PFE : 29.66 (-0.30%)
LLY : 915.04 (+1.11%)
Smartsheet Nears $8 Billion Buyout Deal with Vista and Blackstone

Private equity giants Vista Equity Partners and Blackstone (BX) are nearing a significant acquisition deal to buy Smartsheet, a collaboration-software company, for around $8 billion. Sources familiar with...

SMAR : 50.81 (-1.63%)
BX : 159.66 (+3.05%)
PFE : 29.66 (-0.30%)
CSCO : 51.44 (+1.72%)
AAL : 11.11 (+0.73%)
ASAN : 12.54 (+5.20%)
EDR : 27.71 (+0.25%)

Barchart Exclusives

How Surging AI Demand Could Drive This Dividend Stock Higher
Eaton, a diversified power management company, is poised to benefit from the surging demand for AI-driven data centers, with its innovative power solutions and strong dividend growth making it an attractive investment opportunity. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar